GLP Research · T-GLP 2
T-GLP 2 (60mg)
from $189.00
Mechanism of Action
Therapeutic GLP-2 analog for intestinal epithelial homeostasis and metabolic pathway research.
Research Vectors
- Metabolic research
- GLP-2 pathway
- Epithelial studies
* Fulfillment subject to stock availability
For research purposes only.This compound is intended strictly for in-vitro laboratory research conducted by qualified professionals. It is not a drug, supplement, cosmetic, or food. It is not intended for use in or on humans or animals and has not been evaluated by the FDA for any purpose.
GIP / GLP-1 Dual Agonist · 60mg
Tirzepatide Protocol Reference Protocol
Dual agonist, once-weekly subcutaneous injection. Metabolic pathway support.
BAC Water Reconstitution
Dilution volume: Add 2 mL BAC water to a 60 mg vial.
Quick-Draw Equivalents:
8 Units0.08 mL = 2.5 mg
10 Units0.10 mL = 3.0 mg
15 Units0.15 mL = 4.5 mg
20 Units0.20 mL = 6.0 mg
25 Units0.25 mL = 7.5 mg
Timing & Administration
☀️ Morning
Most common. Allows monitoring of early side effects during waking hours.
🌙 Night
Some prefer nighttime if fatigue is experienced after dosing.
Titration Schedule Guide
Starting dose of 2.5 mg weekly matches the standard protocol. Hold at each dose step for 4 weeks before increasing.
| Phase | Dose | Draw Volume | Protocol Notes |
|---|---|---|---|
| Weeks 1-4 | 2.5-3.0 mg weekly | 8-10 Units | FDA-approved starting range. Hold for minimum 4 weeks before increasing. |
| Weeks 5-8 | 5.0-6.0 mg weekly | 16-20 Units | Increase gradually only after 4 full weeks at prior dose. |
| Weeks 9+ | 7.5 mg+ weekly | 25+ Units | Only if needed and tolerated. Max recommended dose is 15 mg weekly (50 units). |
Cycle Protocol
Prioritize protein intake and hydration. Eating smaller meals reduces nausea. Once-weekly injection.
Observed Side Effects
NauseaConstipationDiarrheaVomitingFatigueHypoglycemia (if co-administered)
Safety Notice: Monitor for severe abdominal pain, gallbladder issues, dehydration, or signs of allergic reactions.